2024 Annual Meeting | Industry Therapeutic Update from Sanofi: Non-Relapsing SPMS: Perspectives From a Person Living with MS and a Review of the Underlying CNS Biology

Date Monday 04/15/24

Time 06:00 PM - 08:00 PM MDT Add To Calendar

Location Embassy Suites | Crystal Ballroom

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Jennifer Graves, MD, PhD, Anthony Traboulsee, MD

Topic(s) General Neurology, Multiple Sclerosis

Learning Objectives Despite current treatment options, disability accumulation remains a reality for many people living with MS, including those with non-relapsing SPMS. In this Sanofi medical ITU, we will hear from a person living with SPMS through a candid conversation with a physician about their MS journey. In addition, an MS expert will discuss the underlying biology of SPMS and how changes in the CNS immune microenvironment are thought to drive non-relapsing biology. BTK within disease-associated microglia will be presented as a potential target for future therapies to slow disability accumulation across the spectrum of MS.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM MDT	Speaker	Industry Therapeutic Update from Sanofi: Non-Relapsing SPMS: Perspectives From a Person Living with MS and a Review of the Underlying CNS Biology

Faculty Disclosures
Jennifer Graves, MD, PhD	Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Graves has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MSJ. The institution of Dr. Graves has received research support from Octave. The institution of Dr. Graves has received research support from Sanofi. The institution of Dr. Graves has received research support from EMD Serono.
Anthony Traboulsee, MD	Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Genzyme.